Hoertel et al. Biol Psychiatry Glob Open Sci. 2022


Risk of death in individuals hospitalized for COVID-19 with and without psychiatric disorders: an observational multicenter study in France.  Hoertel N, Sánchez-Rico M, Muela P, Abellán M, Blanco C, Leboyer M, Cougoule C, Gulbins E, Kornhuber J, Carpinteiro A, Becker KA, Vernet R, Beeker N, Neuraz A, Alvarado JM, Herrera-Morueco JJ, Airagnes G, Lemogne C, Limosin F.Biol Psychiatry Glob Open Sci. 2022 Jan 4;. doi: 10.1016/j.bpsgos.2021.12.007. [Epub ahead of print] PubMed PMID: 35013734; PubMed Central PMCID: PMC8730644. OPEN ACCES. Download from HAL-INSERM


Background: Prior research suggests that psychiatric disorders could be linked to increased mortality among patients with COVID-19. However, whether all or specific psychiatric disorders are intrinsic risk factors of death in COVID-19, or whether these associations reflect the greater prevalence of medical risk factors in people with psychiatric disorders, has yet to be evaluated.

Methods: We performed an observational multicenter retrospective cohort study to examine the association between psychiatric disorders and mortality among patients hospitalized for laboratory-confirmed COVID-19 at 36 Greater Paris University hospitals.

Results: Of 15,168 adult patients, 857 (5.7%) had an ICD-10 diagnosis of psychiatric disorder. Over a mean follow-up of 14.6 days (SD=17.9), death occurred in 326/857 (38.0%) patients with a diagnosis of psychiatric disorder versus 1,276/14,311 (8.9%) in patients without such a diagnosis (OR=6.27; 95%CI=5.40-7.28; p<0.01). When adjusting for age, sex, hospital, current smoking status, and medications according to compassionate use or as part of a clinical trial, this association remained significant (AOR=3.27; 95%CI=2.78-3.85; p<0.01). However, additional adjustments for obesity and number of medical conditions resulted in a non-significant association (AOR=1.02; 95%CI=0.84-1.23; p=0.86). Exploratory analyses following the same adjustments suggest that a diagnosis of mood disorders was significantly associated with reduced mortality, which might be explained by the use of antidepressants.

Conclusions: These findings suggest that the increased risk of COVID-19-related mortality in individuals with psychiatric disorders hospitalized for COVID-19 might be explained by the greater number of medical conditions and the higher prevalence of obesity in this population, but not by the underlying psychiatric disease.

Keywords: COVID-19; SARS-COV-2; antidepressants; comorbidity; mental disorders; mood disorders; mortality; obesity; psychiatric disorders; risk of death.

This part of the website could either be in French or English, depending on the sources of the actualities.


 25 avril 2023
Hemorrhagic Stroke: Current Research regarding Etiological Diagnosis
 01 mars 2023 20 mars 2023
Semaine du Cerveau 25ème édition
 01 mars 2023 14 mars 2023
Conférence inaugurale de la Semaine du Cerveau: Neurosciences et Psychiatrie, un vertueux mariage
 24 février 2023 18 mars 2023
NeuroFrance 2023
 02 septembre 2022
The reciprocal interplay between nutrient sensing and secretory pathways defines cellular homeostasis
 01 juillet 2022
Cortical wiring by synapsespecific control of local protein synthesis
 20 juin 2022
Demars et al. Curr Biol. 2022
 03 juin 2022
Programming neural cells for disease modelling and therapy development
 06 mai 2022
Phenomenology and pathophysiology of antipsychotic-induced compulsive behaviour
 01 avril 2022
Medial Septum cholinergic inputs to CA2: a new role in social novelty discrimination
 04 mars 2022
Molecular Dissection of Selective Neuronal Vulnerability in Alzheimer's Disease
 23 février 2022
Sánchez-Rico et al. J Travel Med. 2022
 04 février 2022
Quantitative analysis and modelling of dendrite growth
 20 janvier 2022
Hoertel et al. Biol Psychiatry Glob Open Sci. 2022
 07 janvier 2022
Neurobiology of social and non social decision-making processes in mouse models
 21 décembre 2021 31 décembre 2021
Psychiatry and Neuroscience Seminar Series 2021
 03 décembre 2021
Deconstructing the role of dopamine signaling in defensive behaviors
 05 novembre 2021
Molecular mechanisms of synaptic development: insights from a human-specific gene
 01 octobre 2021
Implementing motor learning in stroke neurorehabilitation
 03 septembre 2021
Neurodegenerative diseases in the age of genetic engineering